Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Jagdeep S S SinghIfy R MordiKeeran VicknesonAmir FathiPeter T DonnanMohapradeep MohanAnna Maria J ChoyStephen GandyJacob GeorgeFaisel KhanEwan R PearsonJ Graeme HoustonAllan D StruthersChim C LangPublished in: Diabetes care (2020)
We were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.
Keyphrases
- heart failure
- left ventricular
- acute heart failure
- phase iii
- clinical trial
- study protocol
- acute myocardial infarction
- health insurance
- metabolic syndrome
- hypertrophic cardiomyopathy
- mitral valve
- atrial fibrillation
- phase ii
- open label
- aortic stenosis
- coronary artery disease
- adipose tissue
- left atrial
- glycemic control